Twenty-eight outpatients with schizophrenia (aged 18-64 years) were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks. The primary outcome was proportion of participants with >5% weight loss. All 28 participants completed the study; 3/14 in the exenatide group and 2/14 in the usual care group had type 2 diabetes.
Subjects
Diabetes / Diet and Nutrition / Mental Health / Metabolic and Endocrine / Obesity / Schizophrenia
DOI Number
Data set type
The type of data shared will depend on the conditions of an HREC waiver, as current ethical approval does not allow for sharing of IPD.
ANZCTR reference number
Publication
Siskind, D. J., Russell, A. W., Gamble, C., Winckel, K., Mayfield, K., Hollingworth, S., Hickman, I., Siskind, V., & Kisely, S. (2018). Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes, obesity & metabolism, 20(4), 1050–1055. https://doi.org/10.1111/dom.13167
Dataset Access Link
Protocol
https://www.anzctr.org.au/Steps11and12/368512-(Uploaded-19-07-2023-12-52-30)-Study-related%20document.docx